Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism)

Abstract

Background: Thromboembolic disease is a major cause of mortality and morbidity Current anticoagulant therapies have several caveats in the clinical use. New oral antithrombin (Dabigatran) provides comparable or superior thromboprophylaxis in multiple thromboembolic disease indications compared to standard of care.Aim of this work: To evaluate the role of a new oral antithrombin, in management of thrombophilia presented with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction).Patient and methods: This work was done on 100 patients with thrombophilia associated with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction). They were divided into 2 groups Group I: treated by LMW heparin. Group II: treated by dabigatran. The following was done for all patients. Thorough history taking, complete physical examination, investigations including CT, D Dimer, INR, APTT, Platelet count, Chest X ray P/A and lateral view, CT chest and/or Brain, ECG, CKMB and troponin when needed.Results: The percentage of Stroke/TIA, AF/MI, PE, mixed and peripheral thrombotic events were 30, 24, 23, 26 and 6 patients respectively.

Some features of the diagnostics of thrombophilia. Case report

“…Последние субанализы многоцентровых исследований показали нецелесообразность приема ривароксабана и апиксабана у пациентов с антифосфолипидным синдромом, что четко прописано в инструкции по применению данных препаратов. Тем не менее с учетом отсутствия необходимости лабораторного контроля и достаточно безопасного профиля в плане геморрагических осложнений данные препараты продолжают применяться при наличии резистентности к кумаринам или патогенетической обоснованности их использования [8][9][10].…”